Search

Your search keyword '"London Lucien Peng Jin Ooi"' showing total 16 results
Start Over Author "London Lucien Peng Jin Ooi"
16 results on '"London Lucien Peng Jin Ooi"'

1. Resected pancreatic adenocarcinoma: An Asian institution's experience

Author

Kennedy Yao Yi Ng, Edwin Wei Xiang Chow, Bochao Jiang, Cindy Lim, Brian Kim Poh Goh, Ser Yee Lee, Jin Yao Teo, Damien Meng Yew Tan, Peng Chung Cheow, London Lucien Peng Jin Ooi, Pierce Kah Hoe Chow, Joycelyn Jie Xin Lee, Juinn Huar Kam, Ye Xin Koh, Prema Raj Jeyaraj, Ek Khoon Tan, Su Pin Choo, Chung Yip Chan, Alexander Yaw Fui Chung, and David Tai

Subjects
pancreatic adenocarcinoma, prognostic factors, resected, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Pancreatic adenocarcinoma (PDAC) is highly lethal. Surgery offers the only chance of cure, but 5‐year overall survival (OS) after surgical resection and adjuvant therapy remains dismal. Adjuvant trials were mostly conducted in the West enrolling fit patients. Applicability to a general population, especially Asia has not been described adequately. Aim We aimed to evaluate the clinical outcomes, prognostic factors of survival, pattern, and timing of recurrence after curative resection in an Asian institution. Methods and Results The clinicopathologic and survival outcomes of 165 PDAC patients who underwent curative resection between 1998 and 2013 were reviewed retrospectively. Median age at surgery was 62.0 years. 55.2% were male, and 73.3% had tumors involving the head of pancreas. The median OS of the entire cohort was 19.7 months. Median OS of patients who received adjuvant chemotherapy was 23.8 months. Negative predictors of survival include lymph node ratio (LNR) of >0.3 (HR = 3.36, P = .001), tumor site involving the body or tail of pancreas (HR = 1.59, P = .046), presence of perineural invasion (PNI) (HR = 2.36, P = .018) and poorly differentiated/undifferentiated tumor grade (HR = 1.86, P = .058). The median time to recurrence was 8.87 months, with 66.1% and 81.2% of patients developing recurrence at 12 months and 24 months respectively. The most common site of recurrence was the liver. Conclusion The survival of Asian patients with resected PDAC who received adjuvant chemotherapy is comparable to reported randomized trials. Clinical characteristics seem similar to Western patients. Hence, geographical locations may not be a necessary stratification factor in RCTs. Conversely, lymph node ratio and status of PNI ought to be incorporated.

Published
2021
Full Text
View/download PDF

2. Comparison between long and short-term venous patencies after pancreatoduodenectomy or total pancreatectomy with portal/superior mesenteric vein resection stratified by reconstruction type.

Author

Kai Siang Chan, Nandhini Srinivasan, Ye Xin Koh, Ek Khoon Tan, Jin Yao Teo, Ser Yee Lee, Peng Chung Cheow, Prema Raj Jeyaraj, Pierce Kah Hoe Chow, London Lucien Peng Jin Ooi, Chung Yip Chan, Alexander Yaw Fui Chung, and Brian Kim Poh Goh

Subjects
Medicine, Science
Abstract

BackgroundVenous reconstruction has been recently demonstrated to be safe for tumours with invasion into portal vein and/or superior mesenteric vein. This study aims to compare the patency between various venous reconstructions.MethodsThis is retrospective study of 76 patients who underwent pancreaticoduodenectomy or total pancreatectomy with venous reconstruction from 2006 to 2018. Patient demographics, tumour histopathology, morbidity, mortality and patency were studied. Kaplan-Meier estimates were performed for primary venous patency.ResultsSixty-two patients underwent pancreaticoduodenectomy and 14 underwent total pancreatectomy. Forty-seven, 19 and 10 patients underwent primary repair, end-to-end anastomosis and interposition graft respectively. Major morbidity (Clavien-Dindo >grade 2) and 30-day mortality were 14/76(18.4%) and 1/76(1.3%) respectively. There were 12(15.8%) venous occlusion including 4(5.3%) acute occlusions. Overall 6-month, 1-year and 2-year primary patency was 89.1%, 92.5% and 92.3% respectively. 1-year primary patency of primary repair was superior to end-to-end anastomosis and interposition graft (primary repair 100%, end-to-end anastomosis 81.8%, interposition graft 66.7%, p = 0.045). Pairwise comparison also demonstrated superior 1-year patency of primary repair (adjusted p = 0.037). There was no significant difference between the cumulative venous patency for each venous reconstruction method: primary repair 84±6%, end-to-end anastomosis 75±11% and interposition graft 76±15% (p = 0.561).Conclusion1-year primary venous patency of primary repair is superior to end-to-end anastomosis and interposition graft.

Published
2020
Full Text
View/download PDF

4. The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma.

Author

Soo Fan Ang, Elizabeth Shu-Hui Ng, Huihua Li, Yu-Han Ong, Su Pin Choo, Joanne Ngeow, Han Chong Toh, Kiat Hon Lim, Hao Yun Yap, Chee Kiat Tan, London Lucien Peng Jin Ooi, Peng Chung Cheow, Alexander Yaw Fui Chung, Pierce Kah Hoe Chow, Kian Fong Foo, and Min-Han Tan

Subjects
Medicine, Science
Abstract

Surgery is the primary curative option in patients with hepatocellular carcinoma (HCC). Current prognostic models for HCC are developed on datasets of primarily patients with advanced cancer, and may be less relevant to resectable HCC. We developed a postoperative nomogram, the Singapore Liver Cancer Recurrence (SLICER) Score, to predict outcomes of HCC patients who have undergone surgical resection.Records for 544 consecutive patients undergoing first-line curative surgery for HCC in one institution from 1992-2007 were reviewed, with 405 local patients selected for analysis. Freedom from relapse (FFR) was the primary outcome measure. An outcome-blinded modeling strategy including clustering, data reduction and transformation was used. We compared the performance of SLICER in estimating FFR with other HCC prognostic models using concordance-indices and likelihood analysis.A nomogram predicting FFR was developed, incorporating non-neoplastic liver cirrhosis, multifocality, preoperative alpha-fetoprotein level, Child-Pugh score, vascular invasion, tumor size, surgical margin and symptoms at presentation. Our nomogram outperformed other HCC prognostic models in predicting FFR by means of log-likelihood ratio statistics with good calibration demonstrated at 3 and 5 years post-resection and a concordance index of 0.69. Using decision curve analysis, SLICER also demonstrated superior net benefit at higher threshold probabilities.The SLICER score enables well-calibrated individualized predictions of relapse following curative HCC resection, and may represent a novel tool for biomarker research and individual counseling.

Published
2015
Full Text
View/download PDF

5. Data from Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model

Author

Paula Yeng Po Lam, Kam Man Hui, Kiat Hon Lim, London Lucien Peng Jin Ooi, Alexander Yaw Fui Chung, Hung Huynh, and Kian Chuan Sia

Abstract

Gene regulation of many key cell-cycle players in S-, G2 phase, and mitosis results from transcriptional repression in their respective promoter regions during the G0 and G1 phases of cell cycle. Within these promoter regions are phylogenetically conserved sequences known as the cell-cycle–dependent element (CDE) and cell-cycle genes homology regions (CHR) sites. Thus, we hypothesize that transcriptional regulation of cell-cycle regulation via the CDE/CHR region together with liver-specific apolipoprotein E (apoE)-hAAT promoter could bring about a selective transgene expression in proliferating human hepatocellular carcinoma. We show that the newly generated vector AH-6CC-L2C could mediate hepatocyte-targeted luciferase gene expression in tumor cells and freshly isolated short-term hepatocellular carcinoma cultures from patient biopsy. In contrast, normal murine and human hepatocytes infected with AH-6CC-L2C expressed minimal or low luciferase activities. In the presence of prodrug 5-fluorocytosine (5-FC), AH-6CC-L2C effectively suppressed the growth of orthotopic hepatocellular carcinoma patient-derived xenograft mouse model via the expression of yeast cytosine deaminase (yCD) that converts 5-FC to anticancer metabolite 5-fluoruracil. More importantly, we show that combination treatment of AH-6CC-L2C with an EZH2 inhibitor, DZNep, that targets EpCAM-positive hepatocellular carcinoma, can bring about a greater therapeutic efficacy compared with a single treatment of virus or inhibitor. Our study showed that targeting proliferating human hepatocellular carcinoma cells through the transcriptional control of therapeutic gene could represent a feasible approach against hepatocellular carcinoma. Mol Cancer Ther; 12(8); 1651–64. ©2013 AACR.

Published
2023

6. Supplementary Table 1 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

Author

Patrick Tan, Bin Tean Teh, Chawalit Pairojkul, Tatsuhiro Shibata, Steven G. Rozen, Raluca Gordân, Ludmil B. Alexandrov, Young Nyun Park, Hyungjin Rhee, André Luiz Vettore, André Lopes Carvalho, Di-Xian Luo, Jiaming Lai, Aldo Scarpa, Ming-Chin Yu, Sen-Yung Hsieh, Philippe Broet, Irinel Popescu, Dan G. Duda, Simona Dima, Kiat Hon Lim, London Lucien Peng Jin Ooi, Alexander Yaw Fui Chung, Pierce Kah-Hoe Chow, Satoshi Yamasaki, Yasuhito Arai, Hiromi Nakamura, Yasushi Totoki, Sopit Wongkham, Puangrat Yongvanit, Vajaraphongsa Bhudhisawasdi, Narong Khuntikeo, John R. McPherson, Jia Liang Loh, Jing Tan, Tse Hui Lim, Alvin Soon Tiong Lim, Stefanus Lie, Vikneswari Rajasegaran, Choon Kiat Ong, Mo Liu, Arnoud Boot, Cedric Chuan Young Ng, Weng Khong Lim, Sanjanaa Nagarajan, Raynoo Thanan, Swe Swe Myint, Su Pin Choo, Ley Moy Ng, Alvin Wei Tian Ng, Sarinya Kongpetch, Vishwa Nellore, Nisha Padmanabhan, Mi Ni Huang, Jing Quan Lim, Chern Han Yong, Ioana Cutcutache, and Apinya Jusakul

Abstract

Summary of Patients and Clinical Data.

Published
2023

7. Supplementary Figures 1-6 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

Author

Patrick Tan, Bin Tean Teh, Chawalit Pairojkul, Tatsuhiro Shibata, Steven G. Rozen, Raluca Gordân, Ludmil B. Alexandrov, Young Nyun Park, Hyungjin Rhee, André Luiz Vettore, André Lopes Carvalho, Di-Xian Luo, Jiaming Lai, Aldo Scarpa, Ming-Chin Yu, Sen-Yung Hsieh, Philippe Broet, Irinel Popescu, Dan G. Duda, Simona Dima, Kiat Hon Lim, London Lucien Peng Jin Ooi, Alexander Yaw Fui Chung, Pierce Kah-Hoe Chow, Satoshi Yamasaki, Yasuhito Arai, Hiromi Nakamura, Yasushi Totoki, Sopit Wongkham, Puangrat Yongvanit, Vajaraphongsa Bhudhisawasdi, Narong Khuntikeo, John R. McPherson, Jia Liang Loh, Jing Tan, Tse Hui Lim, Alvin Soon Tiong Lim, Stefanus Lie, Vikneswari Rajasegaran, Choon Kiat Ong, Mo Liu, Arnoud Boot, Cedric Chuan Young Ng, Weng Khong Lim, Sanjanaa Nagarajan, Raynoo Thanan, Swe Swe Myint, Su Pin Choo, Ley Moy Ng, Alvin Wei Tian Ng, Sarinya Kongpetch, Vishwa Nellore, Nisha Padmanabhan, Mi Ni Huang, Jing Quan Lim, Chern Han Yong, Ioana Cutcutache, and Apinya Jusakul

Abstract

Supplementary Figure 1. Unsupervised Clustering on CCA samples. Supplementary Figure 2. Alterations Found in CCA Clusters. Supplementary Figure 3. MAP2K4 Homozygous Deletions and ERBB2 Amplifications. Supplementary Figure 4. Alterations Related to Structural Variations Found in CCAs. Supplementary Figure 5. FIREFLY Analysis of Pathways Systematically Dysregulated by Somatic Promoter Mutations that Alter Transcription Factor Binding. Supplementary Figure 6. Epigenetic Clusters and Mutation Signatures.

Published
2023

8. Supplementary Figure S1 from Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model

Author

Paula Yeng Po Lam, Kam Man Hui, Kiat Hon Lim, London Lucien Peng Jin Ooi, Alexander Yaw Fui Chung, Hung Huynh, and Kian Chuan Sia

Abstract

Supplementary Figure S1 - PDF file 87K, Gene expression of AH-6CC-L2C in proliferating and G1-arrested PLC/PRF/5 cells. Cell cycle-regulated luciferase reporter activity in proliferating and G1-arrested PLC/PRF/5 cells after 48 h in A, post transfection with pAH-6CC-L2C or B, post infection with AH-6CC-L2C at MOI of 1. Total RLU was normalized with total protein contents and % of eGFP-positive cells representing the transfection efficiency. Data were presented as mean plus-minus SEM, n = 3. C, Corresponding cell cycle profiles of proliferating and G1-arrested PLC/PRF/5 cells as analyzed by FACS analysis

Published
2023

9. Supplementary Table 4 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

Author

Patrick Tan, Bin Tean Teh, Chawalit Pairojkul, Tatsuhiro Shibata, Steven G. Rozen, Raluca Gordân, Ludmil B. Alexandrov, Young Nyun Park, Hyungjin Rhee, André Luiz Vettore, André Lopes Carvalho, Di-Xian Luo, Jiaming Lai, Aldo Scarpa, Ming-Chin Yu, Sen-Yung Hsieh, Philippe Broet, Irinel Popescu, Dan G. Duda, Simona Dima, Kiat Hon Lim, London Lucien Peng Jin Ooi, Alexander Yaw Fui Chung, Pierce Kah-Hoe Chow, Satoshi Yamasaki, Yasuhito Arai, Hiromi Nakamura, Yasushi Totoki, Sopit Wongkham, Puangrat Yongvanit, Vajaraphongsa Bhudhisawasdi, Narong Khuntikeo, John R. McPherson, Jia Liang Loh, Jing Tan, Tse Hui Lim, Alvin Soon Tiong Lim, Stefanus Lie, Vikneswari Rajasegaran, Choon Kiat Ong, Mo Liu, Arnoud Boot, Cedric Chuan Young Ng, Weng Khong Lim, Sanjanaa Nagarajan, Raynoo Thanan, Swe Swe Myint, Su Pin Choo, Ley Moy Ng, Alvin Wei Tian Ng, Sarinya Kongpetch, Vishwa Nellore, Nisha Padmanabhan, Mi Ni Huang, Jing Quan Lim, Chern Han Yong, Ioana Cutcutache, and Apinya Jusakul

Abstract

Structural Variations across 71 WGS CCAs.

Published
2023

11. Supplementary Materials and Methods from Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model

Author

Paula Yeng Po Lam, Kam Man Hui, Kiat Hon Lim, London Lucien Peng Jin Ooi, Alexander Yaw Fui Chung, Hung Huynh, and Kian Chuan Sia

Abstract

Supplementary Materials and Methods - PDF file 94K, Supplementary Materials and Methods including helper virus-free packaging, isolation of single cells suspension, immunofluorescent (IF) staining, immunohistochemical (IHC) staining and cell cycle analysis

Published
2023

12. Supplementary Table 3 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

Author

Patrick Tan, Bin Tean Teh, Chawalit Pairojkul, Tatsuhiro Shibata, Steven G. Rozen, Raluca Gordân, Ludmil B. Alexandrov, Young Nyun Park, Hyungjin Rhee, André Luiz Vettore, André Lopes Carvalho, Di-Xian Luo, Jiaming Lai, Aldo Scarpa, Ming-Chin Yu, Sen-Yung Hsieh, Philippe Broet, Irinel Popescu, Dan G. Duda, Simona Dima, Kiat Hon Lim, London Lucien Peng Jin Ooi, Alexander Yaw Fui Chung, Pierce Kah-Hoe Chow, Satoshi Yamasaki, Yasuhito Arai, Hiromi Nakamura, Yasushi Totoki, Sopit Wongkham, Puangrat Yongvanit, Vajaraphongsa Bhudhisawasdi, Narong Khuntikeo, John R. McPherson, Jia Liang Loh, Jing Tan, Tse Hui Lim, Alvin Soon Tiong Lim, Stefanus Lie, Vikneswari Rajasegaran, Choon Kiat Ong, Mo Liu, Arnoud Boot, Cedric Chuan Young Ng, Weng Khong Lim, Sanjanaa Nagarajan, Raynoo Thanan, Swe Swe Myint, Su Pin Choo, Ley Moy Ng, Alvin Wei Tian Ng, Sarinya Kongpetch, Vishwa Nellore, Nisha Padmanabhan, Mi Ni Huang, Jing Quan Lim, Chern Han Yong, Ioana Cutcutache, and Apinya Jusakul

Abstract

Summary of CCA Alterations.

Published
2023

13. Supplementary Methods and Supplementary Figure and Table Legends from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

Author

Patrick Tan, Bin Tean Teh, Chawalit Pairojkul, Tatsuhiro Shibata, Steven G. Rozen, Raluca Gordân, Ludmil B. Alexandrov, Young Nyun Park, Hyungjin Rhee, André Luiz Vettore, André Lopes Carvalho, Di-Xian Luo, Jiaming Lai, Aldo Scarpa, Ming-Chin Yu, Sen-Yung Hsieh, Philippe Broet, Irinel Popescu, Dan G. Duda, Simona Dima, Kiat Hon Lim, London Lucien Peng Jin Ooi, Alexander Yaw Fui Chung, Pierce Kah-Hoe Chow, Satoshi Yamasaki, Yasuhito Arai, Hiromi Nakamura, Yasushi Totoki, Sopit Wongkham, Puangrat Yongvanit, Vajaraphongsa Bhudhisawasdi, Narong Khuntikeo, John R. McPherson, Jia Liang Loh, Jing Tan, Tse Hui Lim, Alvin Soon Tiong Lim, Stefanus Lie, Vikneswari Rajasegaran, Choon Kiat Ong, Mo Liu, Arnoud Boot, Cedric Chuan Young Ng, Weng Khong Lim, Sanjanaa Nagarajan, Raynoo Thanan, Swe Swe Myint, Su Pin Choo, Ley Moy Ng, Alvin Wei Tian Ng, Sarinya Kongpetch, Vishwa Nellore, Nisha Padmanabhan, Mi Ni Huang, Jing Quan Lim, Chern Han Yong, Ioana Cutcutache, and Apinya Jusakul

Abstract

Further details of methods, in addition to the supplementary figure and table legends.

Published
2023

14. Supplementary Table 2 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

Author

Patrick Tan, Bin Tean Teh, Chawalit Pairojkul, Tatsuhiro Shibata, Steven G. Rozen, Raluca Gordân, Ludmil B. Alexandrov, Young Nyun Park, Hyungjin Rhee, André Luiz Vettore, André Lopes Carvalho, Di-Xian Luo, Jiaming Lai, Aldo Scarpa, Ming-Chin Yu, Sen-Yung Hsieh, Philippe Broet, Irinel Popescu, Dan G. Duda, Simona Dima, Kiat Hon Lim, London Lucien Peng Jin Ooi, Alexander Yaw Fui Chung, Pierce Kah-Hoe Chow, Satoshi Yamasaki, Yasuhito Arai, Hiromi Nakamura, Yasushi Totoki, Sopit Wongkham, Puangrat Yongvanit, Vajaraphongsa Bhudhisawasdi, Narong Khuntikeo, John R. McPherson, Jia Liang Loh, Jing Tan, Tse Hui Lim, Alvin Soon Tiong Lim, Stefanus Lie, Vikneswari Rajasegaran, Choon Kiat Ong, Mo Liu, Arnoud Boot, Cedric Chuan Young Ng, Weng Khong Lim, Sanjanaa Nagarajan, Raynoo Thanan, Swe Swe Myint, Su Pin Choo, Ley Moy Ng, Alvin Wei Tian Ng, Sarinya Kongpetch, Vishwa Nellore, Nisha Padmanabhan, Mi Ni Huang, Jing Quan Lim, Chern Han Yong, Ioana Cutcutache, and Apinya Jusakul

Abstract

Alterations in CCA Clusters.

Published
2023

15. Supplementary Table 5 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

Author

Patrick Tan, Bin Tean Teh, Chawalit Pairojkul, Tatsuhiro Shibata, Steven G. Rozen, Raluca Gordân, Ludmil B. Alexandrov, Young Nyun Park, Hyungjin Rhee, André Luiz Vettore, André Lopes Carvalho, Di-Xian Luo, Jiaming Lai, Aldo Scarpa, Ming-Chin Yu, Sen-Yung Hsieh, Philippe Broet, Irinel Popescu, Dan G. Duda, Simona Dima, Kiat Hon Lim, London Lucien Peng Jin Ooi, Alexander Yaw Fui Chung, Pierce Kah-Hoe Chow, Satoshi Yamasaki, Yasuhito Arai, Hiromi Nakamura, Yasushi Totoki, Sopit Wongkham, Puangrat Yongvanit, Vajaraphongsa Bhudhisawasdi, Narong Khuntikeo, John R. McPherson, Jia Liang Loh, Jing Tan, Tse Hui Lim, Alvin Soon Tiong Lim, Stefanus Lie, Vikneswari Rajasegaran, Choon Kiat Ong, Mo Liu, Arnoud Boot, Cedric Chuan Young Ng, Weng Khong Lim, Sanjanaa Nagarajan, Raynoo Thanan, Swe Swe Myint, Su Pin Choo, Ley Moy Ng, Alvin Wei Tian Ng, Sarinya Kongpetch, Vishwa Nellore, Nisha Padmanabhan, Mi Ni Huang, Jing Quan Lim, Chern Han Yong, Ioana Cutcutache, and Apinya Jusakul

Abstract

Coverage Statistics and List of Genes for Targeted Sequencing.

Published
2023

16. Biliary-enteric transanastomotic stenting with Intestofix

Author

London Lucien Peng-Jin, Ooi, Yaw-Fui Alexander, Chung, and Wai-Keong, Wong

Subjects
Postoperative Complications, Liver, Anastomosis, Surgical, Polyurethanes, Jejunostomy, Humans, Stents, Constriction, Pathologic
Abstract

Biliary-enteric transanastomotic stenting is useful under adverse local conditions or when small-calibre bile ducts are encountered.A commercially available feeding jejunostomy kit, Intestofix, was inserted transjejunally through the blind loop of a Roux-en-Y hepatico-jejunostomy.The stent splinted the anastomosis to reduce biliary leaks and may help to prevent subsequent stricture formation.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results